Effects of GJE extract treatment decreased protein expression of MMP-12, α-SMA, IL-13, and TGF-β1 levels. by Natnicha Suttawong (22367172)

Charts revealing A) the significant decrease (<i>p</i> < 0.05) in the membrane integrity and B) the significant increase (<i>p</i> < 0.05) in the membrane permeability after treatment with harmalacidine hydrochloride in a representative <i>S. aureus</i> isolate (n = 3 as technical repeats of the same isolate). by Manal A. Alossaimi (10269852)

“…<p>Charts revealing A) the significant decrease (<i>p</i> < 0.05) in the membrane integrity and B) the significant increase (<i>p</i> < 0.05) in the membrane permeability after treatment with harmalacidine hydrochloride in a representative <i>S. aureus</i> isolate (n = 3 as technical repeats of the same isolate).…”

Spatial exploration patterns of non-tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). by Robert Botelho (20308297)

Subjects: “…following chemotherapy treatment…”

Effect of busulfan treatment on vimentin, a supporting cytoskeletal protein. by Lingjun Zhao (21763122)

Effects of busulfan treatment on the ultrastructure of the blood-testis barrier (BTB). by Lingjun Zhao (21763122)

Pan-cancer analyses of ANGPTL4 expression and its prognostic significance in the TCGA database. by Yu Zhang (12946)

Subjects:

Pan-cancer analyses of NFKB2 expression and its prognostic significance in the TCGA database. by Yu Zhang (12946)

Subjects:

Between the PCSO-524 group and the placebo group unpaired comparisons of the change between visits of quality of life and respiratory variables scores. by Nattapon Riengvirodkij (11268720)

Subjects:

A flow diagram outlining the number of dogs in each group during the study (visit 1 = day 0, visit 2 = day 35, and visit 3 = day 70). by Nattapon Riengvirodkij (11268720)

Subjects:

Distribution of quality of life and respiratory variables scores of all 3 visits (visit = day 0, visit 2 = day 35, and visit 3 = day 70) of the PCSO-524 group and the placebo group... by Nattapon Riengvirodkij (11268720)

Subjects:

The baseline characteristics of classifications and body condition score of the 2 groups (frequencies) at entry (visit 1, day 0). by Nattapon Riengvirodkij (11268720)

Subjects:

Distribution of continuous variables of all 3 visits (visit 1 = day 0, visit 2 = day 35, and visit 3 = day 70) of the PCSO-524 group and the placebo group. Results are shown as mea... by Nattapon Riengvirodkij (11268720)

Subjects:

Tricuspid regurgitation pressure gradient of all 17 dogs. by Nattapon Riengvirodkij (11268720)

Subjects:

Tricuspid regurgitation pressure gradient in the PCSO-524 and placebo groups. by Nattapon Riengvirodkij (11268720)

Subjects:

The ATR-CHK1 inhibitor AZD6738 decreases HBV cccDNA level. by Kaitao Zhao (3617825)

Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration. by Denis Mustafov (19137870)

“…<p><b>(A)</b> A significant decrease in the proliferative clonal capacity of U87MG colonies was observed with 70ΜM and 100ΜM SHG-44 treatment. …”

Identification of ACADM, ANGPTL4, and NFKB2 as significant predictors of OS in the TCGA-KIRC cohort. by Yu Zhang (12946)

Subjects:

Treatment at first diagnosis of insomnia disorder (%). by Mingee Choi (15250732)

Subjects:

Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later. by Mingee Choi (15250732)

Subjects:

Mode shapes of the first six modes. by Xueting Ma (390540)